查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2143353

肺炎治療市場：依產品、感染疾病、給藥途徑、最終用途、國家及地區分類－全球產業分析、市場規模、市場佔有率及2026年至2033年預測

Pneumonia Therapeutics Market, By Product, By Infection, By Route of Administration, By End Use, By Country, and By Region -Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
出版日期: | 出版商: AnalystView Market Insights | 英文 300 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計到 2025 年，肺炎治療市場價值將達到 27.801 億美元，並預計從 2026 年到 2033 年將以 9.9% 的複合年成長率成長。

肺炎藥物是指用於治療肺炎的藥物和治療方法。治療包括使用旨在治療、預防和治癒肺炎的藥物。對於細菌性肺炎，通常使用大環內酯類、奎諾酮或頻譜BETA-內醯胺類抗生素；而對於病毒性肺炎，則使用抗病毒藥物。此外，還會使用氧氣療法、支氣管擴張劑、皮質類固醇和靜脈輸液等支持性療法。肺炎藥物的給藥途徑可以是口服、靜脈注射或吸入，這取決於多種因素，包括疾病的嚴重程度、感染的性質、患者的年齡和身體狀況。因此，肺炎治療是任何存在肺炎的環境（例如醫院和加護病房(ICU)）中最重要的環節之一。

肺炎治療市場 - 市場動態

肺炎發病率的上升正在推動市場成長。

肺炎發病率的上升推動了對有效肺炎治療的需求。這是因為隨著越來越多的人患有此病，適當的治療和管理變得至關重要。例如，根據英國氣喘與肺病協會（Asthma+Lung UK Org）2026年2月發布的報告，英格蘭醫院因肺炎患者緊急住院的人數從461,995人增加到579,475人，兩年內增加了25.4%。肺炎病例總數為567,760例。隨著疾病負擔的加重，對有效肺炎治療和療法的需求預計將會上升。

肺炎治療市場－市場細分分析：

全球肺炎治療市場按產品、感染疾病類型、給藥途徑、最終用途和地區進行細分。

肺炎的治療涉及多種藥物，從輕度到重度都有涉及。由於藥物在治療細菌、真菌和病毒感染疾病具有高效性，因此在肺炎治療市場中發揮著至關重要的作用。該市場涵蓋了廣泛的藥物，包括抗生素、抗病毒藥物和抗真菌藥物，這些藥物用於治療肺炎並幫助預防併發症相關感染疾病。 2025年7月，賽諾菲收購了ViceBio，獲得了該公司的兩款疫苗：VXB-241，一種針對呼吸道合胞病毒（RSV）和人類偏肺病毒（hMPV）的二價疫苗；以及VXB-251，一種針對這兩種病毒的臨床前三價疫苗。這兩種病毒可引起下呼吸道感染疾病，包括肺炎。預計這些進展將促進用於預防和治療肺炎相關呼吸道感染疾病的藥物的使用。

社區型肺炎 (CAP) 因其高發病率以及對開發有效抗生素和其他治療方法的需求，已成為肺炎治療市場的重要組成部分。 2026 年 7 月，羅氏公司推出了佐拉瓦爾平，這是一種用於治療由抗藥性革蘭氏陰性菌引起的重症肺炎的創新抗生素。該公司表示，肺炎是可以使用這種抗生素治療的嚴重感染疾病之一。預計此類進展將推動對治療重症社區獲得性肺炎的新療法的需求。

肺炎治療市場—區域分析

北美肺炎治療市場的發展主要得益於診斷技術和治療領域的幾項重大進步。例如，根據美國食品藥物管理局(FDA) 預測，到 2026 年 9 月，將有超過 1,600 種獲得 FDA已通過核准的醫療設備在美國投入使用。這些器材採用人工智慧 (AI) 技術，旨在實現疾病的早期檢測、透過醫學診斷提升診斷能力，並提供個人化的醫療診斷、決策和治療方案。 FDA 列舉了這些技術的應用實例，包括用於檢測皮膚癌的 AI 成像工具、利用子宮頸細胞學和眼部成像技術檢測糖尿病視網膜病變，以及利用深度學習軟體來提高影像品質。這些醫療設備的應用將加速美國醫療保健產業 AI 驅動型診斷技術的創新。

目錄

第1章：肺炎治療藥物市場概覽

  • 分析範圍
  • 市場估算期

第2章執行摘要

  • 市場區隔
  • 競爭考察

第3章：肺炎治療藥物的主要市場趨勢

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 未來市場趨勢

第4章：肺炎治療產業分析

  • PEST分析
  • 波特五力分析
  • 市場成長前景展望圖
  • 管理體制分析

第5章：肺炎治療市場：地緣政治緊張局勢加劇的影響

  • 新冠疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：肺炎治療藥物的市場狀況

  • 肺炎治療藥物市場佔有率分析（2025年）
  • 主要製造商的細分數據
    • 對現有公司的分析
    • 新興企業分析

第7章 肺炎治療市場：依產品分類

  • 概述
    • 基於細分市場的市佔率分析：按產品
    • 製藥
    • 氧氣療法
    • 疫苗

第8章 肺炎治療市場：依感染疾病

  • 概述
    • 細分市場佔有率分析：依感染疾病
    • 院內獲得性肺炎（HAP）
    • 社區型肺炎（CAP）
    • 人工呼吸器相關性肺炎（VAP）

第9章 肺炎治療市場：依給藥途徑分類

  • 概述
    • 按給藥途徑分類的市佔率分析
    • 口服
    • 腸外
    • 其他

第10章：肺炎治療市場：依最終用途分類

  • 概述
    • 基於細分市場的市佔率分析：依最終用途
    • 醫院
    • 專科診所
    • 居家照護
    • 其他

第11章 肺炎治療市場：依地區分類

  • 介紹
  • 北美洲
    • 概述
    • 主要製造商：北美
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 主要製造商：歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 丹麥
    • 其他歐洲國家
  • 亞太地區
    • 概述
    • 主要製造商：亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 台灣
    • 越南
    • 其他亞太國家
  • 拉丁美洲
    • 概述
    • 主要製造商：拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 其他拉丁美洲國家
  • 中東和非洲
    • 概述
    • 主要生產商：中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 伊朗
    • 卡達
    • 其他中東和非洲國家

第12章：主要供應商分析：肺炎治療產業

  • 競爭基準
    • 競爭對手儀錶板
    • 競爭定位
  • 公司簡介
    • Pfizer Inc.
    • Merck & Co., Inc.
    • AstraZeneca PLC
    • GlaxoSmithKline plc（GSK）
    • Sanofi SA
    • F. Hoffmann-La Roche Ltd.
    • Novartis AG
    • Eli Lilly and Company
    • Teva Pharmaceutical Industries Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • Lupin Limited
    • Aurobindo Pharma Limited
    • Baxter International Inc.
    • Mylan NV
    • Cipla Limited
    • Abbott Laboratories
    • Others

第13章：AnalystView 的全景視圖

簡介目錄
Product Code: ANV7595

Pneumonia Therapeutics market size was valued at US$ 2,780.1 Million in 2025, expanding at a CAGR of 9.9% from 2026 to 2033.

Pneumonia Therapeutics refers to the medicines and therapeutic approaches used in treating pneumonia. The treatments involve the use of medicines to treat, prevent, and cure the illness. The treatment of pneumonia usually uses antibiotics such as macrolides, quinolones, or broad-spectrum beta-lactams for cases of bacterial pneumonia; antivirals for cases of viral pneumonia; and supportive medications such as oxygen therapies, bronchodilators, corticosteroids, and intravenous fluids. The administration of pneumonia therapeutics can be through the oral route, intravenously, and through inhalation, and this depends on many factors, including the degree of the disease, the nature of the infection, the age of the individual, and the condition of the patient. This makes pneumonia therapeutics one of the most important parts in any setting where there is a disease, including the hospital and intensive care unit settings.

Pneumonia Therapeutics Market- Market Dynamics

Increasing Prevalence Of Pneumonia To Drive Market Growth

The increasing prevalence of pneumonia is driving the demand for effective pneumonia therapeutics, because as more and more patients come up with the disease, there will be the need for appropriate treatment and management. For example, in February 2026, it was revealed by Asthma + Lung UK Org that emergency admission of patients suffering from pneumonia in hospitals in England alone grew to 579,475 as compared to 461,995 cases, representing an increase of 25.4% in two years. There were 567,760 cases of pneumonia. This rising disease burden is expected to increase demand for effective pneumonia therapeutics and treatment options.

Pneumonia Therapeutics Market- Segmentation Analysis:

The Global Pneumonia Therapeutics market is segmented on the basis of Product, Infection, Route of Administration, End Use, and Region.

Drugs play an important part in the therapeutics market of pneumonia due to their efficiency in treating bacteria, fungal, and viral infections, given that there are a lot of drugs available for the treatment of pneumonia ranging from mild to severe pneumonia. The market includes a range of drugs, such as antibiotics, antivirals, and antifungals, among others, that are employed in the treatment of pneumonia and help prevent complications due to pneumonia infections. In July 2025, Sanofi acquired Vicebio and two vaccines from it, namely VXB-241, which is a bivalent vaccine for RSV and hMPV, and VXB-251, which is a preclinical tripartite vaccine for the two viruses. The two viruses cause lower respiratory tract infections, including pneumonia. These developments are expected to support drug adoption for preventing and treating pneumonia-related respiratory infections.

The Community-acquired pneumonia (CAP) is the key segment in the Pneumonia Therapeutics market since there are a number of incidences of pneumonia in the community and there is a need to develop effective antibiotics and other treatments for the management of the disease in the patients. In July 2026, F. Hoffmann-La Roche Ltd. introduced zosurabalpin, which is an innovative antibiotic for the treatment of severe pneumonia caused by drug-resistant Gram-negative bacteria. The company stated that pneumonia is one of the serious infections that can be managed using the antibiotic drug. These developments will drive the demand for new therapies to treat severe cases of community-acquired pneumonia.

Pneumonia Therapeutics Market- Geographical Insights

The Pneumonia Therapeutics market in North America is backed up by some of the key advancements in diagnostic technologies and treatments. For example, in September 2026, per the U.S. Food and Drug Administration (gov), there are more than 1,600 FDA-cleared medical devices in use as of September 2026 in the U.S. that utilize artificial intelligence design in order to enhance diagnostics through early detection and medical diagnosis of diseases, personalized health care diagnostics and decisions, and treatments. FDA gives an example of using such technology through the application of AI-based imaging tools for detecting skin cancer, pap smear and eye images for detecting diabetes retinopathy, and a deep learning software to improve the quality of the picture. The use of such devices would drive innovations in AI-based diagnostic technologies in the U.S. healthcare industry.

Pneumonia Therapeutics Market- Competitive Landscape:

The competitive landscape is characterized by key competitors' focus on product development, strategic acquisitions, and geographical expansion. The main players in this industry are Teva Pharmaceutical Industries Ltd., Sanofi, Novartis AG, Sun Pharmaceutical Industries Ltd., and Merck & Co., Inc. Some of the strategies followed by the main companies in the industry include business development and geographic expansion. For instance, in March 2025, Merck announced that its pneumococcal 21-valent conjugate vaccine, CAPVAXIVE(R), has received approval from the European Commission to prevent invasive pneumococcal disease and pneumococcal pneumonia in adults age 18 years and older. Such strategies are helping in improving the product portfolio of key market participants.

Recent Developments:

In January 2025, Roche advanced zosurabalpin, an investigational antibody that works on Gram-negative bacteria, which are the cause of various infections, such as pneumonia, to late-stage clinical development in order to develop a novel therapeutic option for drug-resistant bacterial infections.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PNEUMONIA THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Pfizer Inc.
  • Merck & Co., Inc.
  • AstraZeneca PLC
  • GlaxoSmithKline plc (GSK)
  • Sanofi S.A.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Eli Lilly and Company
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Lupin Limited
  • Aurobindo Pharma Limited
  • Baxter International Inc.
  • Mylan N.V.
  • Cipla Limited
  • Abbott Laboratories
  • Others

GLOBAL PNEUMONIA THERAPEUTICS MARKET, BY PRODUCT- MARKET ANALYSIS, 2020 - 2033

  • Drugs
  • Oxygen Therapy
  • Vaccine

GLOBAL PNEUMONIA THERAPEUTICS MARKET, BY INFECTION- MARKET ANALYSIS, 2020 - 2033

  • Hospital-acquired Pneumonia (HAP)
  • Community-acquired Pneumonia (CAP)
  • Ventilator-associated Pneumonia (VAP)

GLOBAL PNEUMONIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2020 - 2033

  • Oral
  • Parenteral
  • Others

GLOBAL PNEUMONIA THERAPEUTICS MARKET, BY END USE- MARKET ANALYSIS, 2020 - 2033

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

GLOBAL PNEUMONIA THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Denmark
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Taiwan
  • Vietnam
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Iran
  • Qatar
  • Rest of MEA

Table of Contents

1. Pneumonia Therapeutics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Pneumonia Therapeutics Market Snippet by Product
    • 2.1.2. Pneumonia Therapeutics Market Snippet by Infection
    • 2.1.3. Pneumonia Therapeutics Market Snippet by Route of Administration
    • 2.1.4. Pneumonia Therapeutics Market Snippet by End Use
    • 2.1.5. Pneumonia Therapeutics Market Snippet by Country
    • 2.1.6. Pneumonia Therapeutics Market Snippet by Region
  • 2.2. Competitive Insights

3. Pneumonia Therapeutics Key Market Trends

  • 3.1. Pneumonia Therapeutics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Pneumonia Therapeutics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Pneumonia Therapeutics Market Opportunities
  • 3.4. Pneumonia Therapeutics Market Future Trends

4. Pneumonia Therapeutics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Pneumonia Therapeutics Market : Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Pneumonia Therapeutics Market Landscape

  • 6.1. Pneumonia Therapeutics Market Share Analysis, 2025
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Pneumonia Therapeutics Market - By Product

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product, 2025 & 2033 (%)
    • 7.1.2. Drugs
    • 7.1.3. Oxygen Therapy
    • 7.1.4. Vaccine

8. Pneumonia Therapeutics Market - By Infection

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Infection, 2025 & 2033 (%)
    • 8.1.2. Hospital-acquired Pneumonia (HAP)
    • 8.1.3. Community-acquired Pneumonia (CAP)
    • 8.1.4. Ventilator-associated Pneumonia (VAP)

9. Pneumonia Therapeutics Market - By Route of Administration

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Route of Administration, 2025 & 2033 (%)
    • 9.1.2. Oral
    • 9.1.3. Parenteral
    • 9.1.4. Others

10. Pneumonia Therapeutics Market - By End Use

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End Use, 2025 & 2033 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Specialty Clinics
    • 10.1.4. Homecare
    • 10.1.5. Others

11. Pneumonia Therapeutics Market - By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Pneumonia Therapeutics Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Pneumonia Therapeutics Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
    • 11.3.17. Denmark
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.17.3. Denmark Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 11.3.17.4. Denmark Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
      • 11.3.17.5. Denmark Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.17.6. Denmark Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
    • 11.3.18. Rest of Europe
      • 11.3.18.1. Overview
      • 11.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.18.3. Rest of the Europe Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 11.3.18.4. Rest of the Europe Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
      • 11.3.18.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.18.6. Rest of the Europe Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Pneumonia Therapeutics Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
    • 11.4.16. Taiwan
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.16.3. Taiwan Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 11.4.16.4. Taiwan Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
      • 11.4.16.5. Taiwan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.16.6. Taiwan Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
    • 11.4.17. Vietnam
      • 11.4.17.1. Overview
      • 11.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.17.3. Vietnam Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 11.4.17.4. Vietnam Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
      • 11.4.17.5. Vietnam Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.17.6. Vietnam Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
    • 11.4.18. Rest of APAC
      • 11.4.18.1. Overview
      • 11.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.18.3. Rest of APAC Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 11.4.18.4. Rest of APAC Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
      • 11.4.18.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.18.6. Rest of APAC Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Pneumonia Therapeutics Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Pneumonia Therapeutics Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
    • 11.6.14. Iran
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.14.3. Iran Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 11.6.14.4. Iran Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
      • 11.6.14.5. Iran Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.14.6. Iran Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
    • 11.6.15. Qatar
      • 11.6.15.1. Overview
      • 11.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.15.3. Qatar Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 11.6.15.4. Qatar Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
      • 11.6.15.5. Qatar Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.15.6. Qatar Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
    • 11.6.16. Rest of MEA
      • 11.6.16.1. Overview
      • 11.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.16.3. Rest of MEA Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
      • 11.6.16.4. Rest of MEA Market Size and Forecast, By Infection, 2020 - 2033 (US$ Million)
      • 11.6.16.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.16.6. Rest of MEA Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)

12. Key Vendor Analysis- Pneumonia Therapeutics Industry

  • 12.1. Competitive Benchmarking
    • 12.1.1. Competitive Dashboard
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Pfizer Inc.
    • 12.2.2. Merck & Co., Inc.
    • 12.2.3. AstraZeneca PLC
    • 12.2.4. GlaxoSmithKline plc (GSK)
    • 12.2.5. Sanofi S.A.
    • 12.2.6. F. Hoffmann-La Roche Ltd.
    • 12.2.7. Novartis AG
    • 12.2.8. Eli Lilly and Company
    • 12.2.9. Teva Pharmaceutical Industries Ltd.
    • 12.2.10. Sun Pharmaceutical Industries Ltd.
    • 12.2.11. Lupin Limited
    • 12.2.12. Aurobindo Pharma Limited
    • 12.2.13. Baxter International Inc.
    • 12.2.14. Mylan N.V.
    • 12.2.15. Cipla Limited
    • 12.2.16. Abbott Laboratories
    • 12.2.17. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us